Ser1504

Site Information
sFEILRGsDGEDsAs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447669

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Relevant cell line - cell type - tissue:	32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 7 ) , 32Dcl3 (myeloid) ( 7 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , Hepa 1-6 (epithelial) ( 8 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 2 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 2 ) , HL-1 (myocyte) ( 2 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 3 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 3 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 4 ) , MEF (fibroblast) ( 3 ) , spleen ( 6 ) , T lymphocyte-spleen ( 5 ) , testis ( 6 )

In vivo Characterization

Methods used to characterize site in vivo:

mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )

Relevant cell line - cell type - tissue:

32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 7 ) , 32Dcl3 (myeloid) ( 7 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , Hepa 1-6 (epithelial) ( 8 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 2 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 2 ) , HL-1 (myocyte) ( 2 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 3 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 3 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 4 ) , MEF (fibroblast) ( 3 ) , spleen ( 6 ) , T lymphocyte-spleen ( 5 ) , testis ( 6 )

Upstream Regulation
Regulatory protein:	FLT3 (mouse) ( 7 ) , RICTOR (mouse) ( 3 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
3	Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3 23429704 Curated Info
4	Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6 21659605 Curated Info
5	Navarro MN, et al. (2011) Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 12, 352-61 21399638 Curated Info
6	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
7	Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39 19854140 Curated Info
8	Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46 18846507 Curated Info